Experian Health launches three new revenue management systems

Revenue cycle management company Experian Health is launching three new products that will expand its portfolio of revenue systems it offers to healthcare organizations.

Experian, which has more than 350,000 clients, offers economic and business guidance to healthcare providers.

The three new systems include Denial Workflow Manager, Compliance Manager and Patient Financial Clearance, according to a statement from Experian. 

"Healthcare organizations must continually adapt and evolve, as the healthcare industry exists in a state of constant flux," said Scott Bagwell, president of Experian Health, in a statement. "By committing ourselves to developing innovative solutions, we are able to help transform the industry, as well as empower healthcare providers to stay ahead of the game and improve their bottom line."

The Denial Workflow Manager uses analytics, workflow tools and claim status to manage patient claim denials. The Compliant Manager helps healthcare organizations better understand information about their collection agencies like their licensing companies, reputations and compliance scores. The Patient Financial Clearance shows healthcare providers how to collect bills from patients by analyzing Medicaid eligibility, their likelihood of paying bills and calculating payment plans.

Experian will present the three new systems at the 2016 HFMA National Institute in Las Vegas, which runs June 26-29.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.